Görüntüleme
10
İndirme
3
Amaç: Otoimmun Hemolitik Anemi (OİHA), hastanın kendi eritrositlerine karşı gelişen antikorlar nedeni ile anemi gelişen bir hastalıktır. İdiopatik olabileceği gibi altta yatan ikincil bir nedenle de gelişebilir. Bu çalışmada OİHA nedenleri, tedavi yaklaşımları ve prognozları tartışılmıştır. Gereç ve yöntemler: Nisan 2014-Nisan 2019 yılları arasında Recep Tayyip Erdoğan Üniversitesi Tıp Fakültesi Hastanesi İç Hastalıkları servislerinde OİHA tanısı alan 9 hastanın tıbbi kayıtları retrospektif olarak değerlendirilmiştir. Hastaların demografik özellikleri, ek hastalıkları, kullandıkları ilaçlar, kan tetkikleri, radyolojik verileri ve uygulanan tedaviler incelenmiştir. Bulgular: OİHA tanısı alan ortalama yaşı 65,8 yıl , 3’ü erkek 6’i kadın olan toplam 9 hasta değerlendirilmiştir. 2 hastada etyolojide ilaç, 2 hastada SLE(Sistemik Lupus Eritematosis), 1 hastada NHL(NonHodgkin Lenfoma), 1’inde meme kanseri, 1’inde mide kanseri, 1 hastada idiopatik, 1 hastada ise ileri tetkiğe izin verilemediği için etyolojisi saptanamamıştır. Hastaların hepsinde intra venöz 6-8 haftalık prednizolon tedavisinin ardından hemoliz tablolarının düzeldiği görülmüştür. NHL olan hastanın nüks olduğu saptanmıştır ve hastaya primer hastalığına yönelik tedavi başlanmıştır. Hastaların hiçbirinde mortalite görülmemiştir. Sonuç: OİHA tanısı klinik ve laboratuvar bulgularla konulur. OİHA, önemli morbidite ve mortalite nedeni olabilir. Uygun tanı ve tedavi yaklaşımıyla morbidite ve mortaliteyi azaltmak mümkündür.
Objective: Autoimmune hemolytic anemia (OHRA) is anemia that develops due to antibodies against the patient's own erythrocytes. It may be idiopathic or may develop for a underlying secondary cause. In this study, the reasons, treatment approaches and prognosis of OIBA are discussed. Material and methods: Medical records of 9 patients diagnosed with OIH between April 2014 and April 2019 in Recep Tayyip Erdogan University Medical Faculty Hospital Internal Medicine Department were retrospectively evaluated. Patients' demographic characteristics, comorbidities, drugs used, blood tests, radiological data and treatments were examined. Results: A total of 9 patients (3 male, 6 female) with an average age of 65.8 years were evaluated. The etiology could not be determined because 2 patients had no etiology of drug, 2 had SLE (Systemic Lupus Erythematosis), 1 had NHL (NonHodgkin Lymphoma), 1 had breast cancer, 1 had stomach cancer, 1 had idiopathic and 1 had no further investigation. In all patients, hemolysis improved after 6 to 8 weeks of prednisolone treatment. The patient with NHL had a recurrence, and treatment for primary disease was initiated. None of the patients had mortality. The diagnosis of OIDA is made by clinical and laboratory findings. OIBA can be a major cause of morbidity and mortality. It is possible to reduce morbidity and mortality with appropriate diagnosis and treatment approach.
Objective: Autoimmune Hemolytic Anemia (OHRA) is anemia that develops due to antibodies against the patient's own erythrocytes. It may be idiopathic or may develop for an underlying secondary cause. In this study, the reasons, treatment approaches and prognosis of OIBA are discussed. Material and methods: Medical records of 9 patients diagnosed with OIH between April 2014 and April 2019 in Recep Tayyip Erdogan University Medical Faculty Hospital Internal Medicine Department were retrospectively evaluated. Patients' demographic characteristics, comorbidities, drugs used, blood tests, radiological data and treatments were examined. Results: A total of 9 patients (3 male, 6 female) with a mean age of 65.8 years were evaluated. The etiology could not be determined because 2 patients had no etiology of drug, 2 had SLE (Systemic Lupus Erythematosis), 1 had NHL (NonHodgkin Lymphoma), 1 had breast cancer, 1 had stomach cancer, 1 had idiopathic and 1 had no further investigation. In all patients, hemolysis improved after 6 to 8 weeks of prednisolone treatment. The patient with NHL had a relapse, and treatment for primary disease was initiated. None of the patients had mortality. Conclusion: The diagnosis of OIDA is made by clinical and laboratory findings. OIBA can be a major cause of morbidity and mortality. It is possible to reduce morbidity and mortality with appropriate diagnosis and treatment approach.
Alan : Sağlık Bilimleri
Dergi Türü : Uluslararası
Makale Detay 
Benzer Makaleler
PDF Görüntüle
Dergi Bilgisi
Eseri Dinleyin
Alıntı Yap
Bu Sayfayı Yazdırın
Paylaş
Mendeley
